NCT01836276

Understanding Disparities in Quitting in African American and White Smokers

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 449 (actual)
• Sponsor: Nikki Nollen, PhD, MA · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to describe the differences in quitting smoking between African Americans (AA) and White smokers treated with varenicline.

Detailed description

While many studies have evaluated the use of drugs for quitting smoking among Whites, few have assessed efficacy with AAs. Racial/ethical differences in smoking are well documented. AAs smoke less than White smokers but experience disproportionately greater smoking disease and death. Past studies by the researchers in this study looked at how effective other smoking cessation methods are in AAs. These methods included nicotine gum, nicotine patch and buproprion sustained release. This study will be evaluating varenicline in both AA and White smokers. There has not been a study conducted yet to prospectively research AA-White differences in smoking cessation and also to examine potential causal pathways explaining AA-White differences in quitting.

Conditions

• Smoking Cessation

Interventions

Type	Name	Description
DRUG	Varenicline	1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines

Timeline

• Start date: 2013-02-01
• Primary completion: 2017-04-01
• Completion: 2017-04-01
• First posted: 2013-04-19
• Last updated: 2018-10-24
• Results posted: 2018-09-21

Locations

2 sites across 1 country: United States